Enfuvirtide | CAS# 159519-65-0 | HIV INFECTIONS and AIDS

MedKoo Cat#: 414017 | Name: Enfuvirtide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Enfuvirtide is a synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.

Chemical Structure

Enfuvirtide

CAS#159519-65-0

Theoretical Analysis

MedKoo Cat#: 414017

Name: Enfuvirtide

CAS#: 159519-65-0

Chemical Formula: C204H301N51O64

Exact Mass: 4489.1866

Molecular Weight: 4491.95

Elemental Analysis: C, 54.55; H, 6.75; N, 15.90; O, 22.79

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 400.00	2 Weeks
10mg	USD 700.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Enfuvirtide; DP178; DP-178; DP 178

IUPAC/Chemical Name

L-Phenylalaninamide, N-acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl-L-leucyl-L-isoleucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-alpha-glutamyl-L-lysyl-L-asparaginyl-L-alpha-glutamyl-L-glutaminyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-leucyl-L-alpha-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-

InChi Key

PEASPLKKXBYDKL-FXEVSJAOSA-N

InChi Code

InChI=1S/C204H301N51O64/c1-20-102(15)166(253-195(310)137(75-100(11)12)239-200(315)150(93-258)251-190(305)143(82-112-90-215-95-219-112)248-203(318)167(103(16)21-2)254-196(311)138(76-101(13)14)240-201(316)151(94-259)252-204(319)168(105(18)260)255-197(312)139(221-106(19)261)78-108-45-47-113(262)48-46-108)202(317)233-131(58-68-164(280)281)178(293)228-130(57-67-163(278)279)182(297)250-149(92-257)198(313)232-125(52-62-155(210)266)179(294)245-145(84-157(212)268)191(306)229-124(51-61-154(209)265)175(290)224-122(49-59-152(207)263)173(288)226-126(53-63-159(270)271)176(291)222-120(43-31-33-69-205)172(287)244-144(83-156(211)267)192(307)231-127(54-64-160(272)273)177(292)225-123(50-60-153(208)264)174(289)227-128(55-65-161(274)275)180(295)235-134(72-97(5)6)185(300)237-133(71-96(3)4)184(299)230-129(56-66-162(276)277)181(296)236-135(73-98(7)8)187(302)247-147(86-165(282)283)194(309)223-121(44-32-34-70-206)171(286)241-140(79-109-87-216-117-40-28-25-37-114(109)117)183(298)220-104(17)170(285)249-148(91-256)199(314)238-136(74-99(9)10)186(301)242-142(81-111-89-218-119-42-30-27-39-116(111)119)189(304)246-146(85-158(213)269)193(308)243-141(80-110-88-217-118-41-29-26-38-115(110)118)188(303)234-132(169(214)284)77-107-35-23-22-24-36-107/h22-30,35-42,45-48,87-90,95-105,120-151,166-168,216-218,256-260,262H,20-21,31-34,43-44,49-86,91-94,205-206H2,1-19H3,(H2,207,263)(H2,208,264)(H2,209,265)(H2,210,266)(H2,211,267)(H2,212,268)(H2,213,269)(H2,214,284)(H,215,219)(H,220,298)(H,221,261)(H,222,291)(H,223,309)(H,224,290)(H,225,292)(H,226,288)(H,227,289)(H,228,293)(H,229,306)(H,230,299)(H,231,307)(H,232,313)(H,233,317)(H,234,303)(H,235,295)(H,236,296)(H,237,300)(H,238,314)(H,239,315)(H,240,316)(H,241,286)(H,242,301)(H,243,308)(H,244,287)(H,245,294)(H,246,304)(H,247,302)(H,248,318)(H,249,285)(H,250,297)(H,251,305)(H,252,319)(H,253,310)(H,254,311)(H,255,312)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)/t102-,103-,104-,105+,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,166-,167-,168-/m0/s1

SMILES Code

NC([C@H](CC1=CC=CC=C1)NC([C@H](CC2=CNC3=C2C=CC=C3)NC([C@@H](NC([C@H](CC4=CNC5=C4C=CC=C5)NC([C@@H](NC([C@@H](NC([C@H](C)NC([C@H](CC6=CNC7=C6C=CC=C7)NC([C@@H](NC([C@H](CC(O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@]([H])(NC([C@@H](NC([C@@H](NC([C@H](CC8=CN=CN8)NC([C@@]([H])(NC([C@@H](NC([C@@H](NC([C@@]([H])(NC([C@H](CC9=CC=C(C=C9)O)NC(C)=O)=O)[C@H](O)C)=O)CO)=O)CC(C)C)=O)[C@@H](C)CC)=O)=O)CO)=O)CC(C)C)=O)[C@@H](C)CC)=O)CCC(O)=O)=O)CCC(O)=O)=O)CO)=O)CCC(N)=O)=O)CC(N)=O)=O)CCC(N)=O)=O)CCC(N)=O)=O)CCC(O)=O)=O)CCCCN)=O)CC(N)=O)=O)CCC(O)=O)=O)CCC(N)=O)=O)CCC(O)=O)=O)CC(C)C)=O)CC(C)C)=O)CCC(O)=O)=O)CC(C)C)=O)=O)CCCCN)=O)=O)=O)CO)=O)CC(C)C)=O)=O)CC(N)=O)=O)=O)=O

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 4,491.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Dando TM, Perry CM. Enfuvirtide. Drugs. 2003;63(24):2755-66; discussion 2767-8. doi: 10.2165/00003495-200363240-00005. PMID: 14664654. 2: Lalezari JP, Luber AD. Enfuvirtide. Drugs Today (Barc). 2004 Mar;40(3):259-69. doi: 10.1358/dot.2004.40.3.820089. PMID: 15148534. 3: Chen RY, Kilby JM, Saag MS. Enfuvirtide. Expert Opin Investig Drugs. 2002 Dec;11(12):1837-43. doi: 10.1517/13543784.11.12.1837. PMID: 12457443. 4: Sundharkrishnan L, Pilkington DM, North JP. Enfuvirtide-Induced Cutaneous Amyloidosis. Cutis. 2021 Mar;107(3):E15-E16. doi: 10.12788/cutis.0211. PMID: 33956616. 5: Oldfield V, Keating GM, Plosker G. Enfuvirtide: a review of its use in the management of HIV infection. Drugs. 2005;65(8):1139-60. doi: 10.2165/00003495-200565080-00007. Erratum in: Drugs. 2005;65(12):1667. PMID: 15907147. 6: LaBonte J, Lebbos J, Kirkpatrick P. Enfuvirtide. Nat Rev Drug Discov. 2003 May;2(5):345-6. doi: 10.1038/nrd1091. PMID: 12755128. 7: Joly V, Jidar K, Tatay M, Yeni P. Enfuvirtide: from basic investigations to current clinical use. Expert Opin Pharmacother. 2010 Nov;11(16):2701-13. doi: 10.1517/14656566.2010.522178. PMID: 20977403. 8: Foy K, Juethner SN. Enfuvirtide (T-20): potentials and challenges. J Assoc Nurses AIDS Care. 2004 Nov-Dec;15(6):65-71. doi: 10.1177/1055329003256414. PMID: 15538017. 9: Fung HB, Guo Y. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther. 2004 Mar;26(3):352-78. doi: 10.1016/s0149-2918(04)90032-x. PMID: 15110129. 10: Duffalo ML, James CW. Enfuvirtide: a novel agent for the treatment of HIV-1 infection. Ann Pharmacother. 2003 Oct;37(10):1448-56. doi: 10.1345/aph.1D143. PMID: 14519027. 11: Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev. 2005 Jul-Sep;7(3):139-47. PMID: 16302461. 12: Jamjian MC, McNicholl IR. Enfuvirtide: first fusion inhibitor for treatment of HIV infection. Am J Health Syst Pharm. 2004 Jun 15;61(12):1242-7. doi: 10.1093/ajhp/61.12.1242. PMID: 15259753. 13: Morse C, Maldarelli F. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering? J Infect Dis. 2007 Feb 1;195(3):318-21. doi: 10.1086/510539. Epub 2006 Dec 21. PMID: 17205468. 14: Lazzarin A. Enfuvirtide: the first HIV fusion inhibitor. Expert Opin Pharmacother. 2005 Mar;6(3):453-64. doi: 10.1517/14656566.6.3.453. PMID: 15794736. 15: Gerstoft J. Enfuvirtid [Enfuvirtide]. Ugeskr Laeger. 2004 Nov 22;166(48):4355-7. Danish. PMID: 15587625. 16: Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004 Aug;54(2):333-40. doi: 10.1093/jac/dkh330. Epub 2004 Jul 1. PMID: 15231762. 17: Marr P, Walmsley S. Reassessment of enfuvirtide's role in the management of HIV-1 infection. Expert Opin Pharmacother. 2008 Sep;9(13):2349-62. doi: 10.1517/14656566.9.13.2349. PMID: 18710359. 18: Makinson A, Reynes J. The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr Opin HIV AIDS. 2009 Mar;4(2):150-8. doi: 10.1097/COH.0b013e32832498d8. PMID: 19339955. 19: Cervia JS, Smith MA. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis. 2003 Oct 15;37(8):1102-6. doi: 10.1086/378302. Epub 2003 Sep 10. PMID: 14523775. 20: Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov. 2004 Mar;3(3):215-25. doi: 10.1038/nrd1331. PMID: 15031735.

View History

Description:

Chemical Structure

Theoretical Analysis

Price and Availability

Preparing Stock Solutions

View History

Flunoxaprofen

CB-892

CB-83

FG-5803

Iolidonic acid

FFK29

Error message: